DOR BioPharma Announces Publication Of OrBec(R) Clinical Pulmonary Data In Bone Marrow Transplantation
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning in Bone Marrow Transplantation in which they demonstrate that DOR"s lead product orBec(R) (oral beclomethasone dipropionate or BDP) decreases non-infectious inflammation of the lung in acute gastrointestinal Graft-versus-Host disease (GI GVHD) patients who received allogeneic hematopoietic cell transplants (HCT). Non-infectious inflammation of the lung is a common and potentially fatal complication of HCT that decreases the exchange of oxygen and carbon dioxide between the lung and blood and, in its severe form, may present as interstitial pneumonitis. The full article, entitled "Influence of Oral Beclomethasone Dipropionate on Early Non-Infectious Pulmonary Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Medical Devices